Incruse Ellipta is a once-daily inhaled medication used to treat chronic obstructive pulmonary disease (COPD). Its active ingredient, umeclidinium, belongs to a class of drugs called long-acting muscarinic antagonists, or LAMAs. It works by relaxing the muscles around your airways so you can breathe more easily throughout the day.
How Incruse Ellipta Works
Your airways are lined with smooth muscle that can tighten in response to a chemical messenger called acetylcholine. In COPD, this tightening becomes a persistent problem, narrowing the passages that carry air in and out of your lungs. Umeclidinium blocks the receptors (called M2 and M3 receptors) that acetylcholine latches onto, preventing those muscles from contracting. The result is bronchodilation: your airways open wider, and air flows more freely.
Because it’s long-acting, a single inhalation keeps those receptors blocked for roughly 24 hours. That’s what makes it a maintenance treatment rather than a rescue inhaler. You use it every day at the same time to keep your airways consistently open, not during a sudden flare-up when you’re struggling to breathe.
What It’s Approved For
The FDA approves Incruse Ellipta specifically for the maintenance treatment of COPD, which includes chronic bronchitis, emphysema, or a combination of both. It is not approved for asthma and is not intended for use in children. It should also never be used as rescue therapy during an acute breathing emergency or a rapidly worsening episode of COPD. For those situations, you’d rely on a short-acting rescue inhaler instead.
How Well It Works
In a head-to-head clinical trial comparing umeclidinium 62.5 micrograms against tiotropium (another widely used LAMA), umeclidinium produced a statistically significant improvement in lung function. After 85 days, patients on umeclidinium showed 59 milliliters more improvement in trough FEV1, a standard measure of how much air you can force out of your lungs in one second, compared with tiotropium. That may sound modest, but in the context of COPD, where lung function declines progressively, even small sustained improvements translate to noticeably easier breathing.
About 53% of patients on umeclidinium achieved at least a 100-milliliter increase in trough FEV1 from baseline, compared with 45% on tiotropium. Umeclidinium also showed stronger results in the 12 to 24 hour window after dosing, with a 70-milliliter advantage over tiotropium at day 84, suggesting better overnight and early-morning airway control.
How to Use the Ellipta Inhaler
The Ellipta device is designed to be straightforward. Before each use, check the dose counter on the back of the inhaler. Then slide the cover down until you hear a click. That single motion loads one dose of dry powder for you to inhale through the mouthpiece. There’s no shaking, priming, or coordinating a button press with your breath the way some other inhalers require.
Each inhaler comes preloaded with 30 doses, enough for one month of daily use. When fewer than 10 doses remain, the counter turns red as a visual reminder to refill your prescription. Once the counter hits zero, discard the device even if it feels like powder is still inside.
Common Side Effects
Because umeclidinium is an anticholinergic, its side effects stem from blocking acetylcholine not just in the lungs but potentially elsewhere in the body. The most frequently reported issues in clinical trials include upper respiratory tract infections (like the common cold), nasal congestion or sore throat, cough, and joint pain. Most of these are mild and tend to overlap with symptoms COPD patients already experience, which can make them easy to dismiss or hard to distinguish from the disease itself.
Important Safety Considerations
Anticholinergic drugs can affect other parts of the body where acetylcholine plays a role. Two areas that deserve attention are the eyes and the urinary tract. If you have narrow-angle glaucoma, umeclidinium could raise the pressure inside your eyes and worsen the condition. Symptoms to watch for include eye pain, blurred vision, or seeing halos around lights. Similarly, if you have an enlarged prostate or a bladder obstruction, the drug may make it harder to urinate.
The medication powder is formulated with lactose, which contains trace milk proteins. People with a severe allergy to milk proteins (not the same as lactose intolerance) should not use Incruse Ellipta. Immediate allergic reactions, though rare, can include swelling of the face, mouth, or throat and difficulty breathing.
Incruse Ellipta also has the potential to cause paradoxical bronchospasm, meaning your airways suddenly tighten right after inhaling. If you feel your breathing get worse immediately after using the inhaler rather than better, stop using it and seek medical attention.
Where Incruse Ellipta Fits in COPD Treatment
COPD treatment typically follows a stepwise approach. For people with mild symptoms, a single long-acting bronchodilator like Incruse Ellipta may be enough to keep breathing comfortable throughout the day. For more advanced disease, it’s often combined with other medications. In fact, the same Ellipta device platform delivers combination products that pair umeclidinium with a second bronchodilator or an inhaled corticosteroid for patients who need more comprehensive control.
The once-daily dosing and simple inhaler design are practical advantages. Adherence is one of the biggest challenges in COPD management, and a device that requires fewer steps and less frequent dosing removes some of the barriers that cause people to skip treatments. If you’ve been prescribed Incruse Ellipta, using it at the same time each day helps maintain consistent airway opening and gives you the best chance of staying ahead of symptoms rather than reacting to them.